Methylprednisolone in traumatic spinal cord lesions: For the moment no benefit to the patient

W. P. Vandertop, N. C. Notermans, A. Algra

Research output: Contribution to journalReview articleAcademicpeer-review

Abstract

Ever since the publication in 1990 in The New England Journal of Medicine of a multicentre, randomised, double-blind, placebo-controlled trial on the efficacy of methylprednisolone (MP) in the treatment of acute, traumatic spinal cord injury, the advice is to administer MP as soon as possible to every patient presenting a traumatic spinal cord injury. This recommendation has been followed throughout the world, especially by traumatologists, and seems to be above criticism. However, the results of most cited studies, which have had a major influence on the treatment of patients with an acute, traumatic spinal cord lesion, show that the improvements in the neurological condition due to MP cannot be translated into a specific improvement in the functional status. Until it has been proven beyond reasonable doubt that MP can play a significant role in the treatment of these patients, we advise that MP should not be administered to a patient with acute, traumatic spinal cord injury, awaiting the results of more quantitative research. Such research is being performed by the Cochrane Brain and Spinal Cord Injury Group.

Translated title of the contributionMethylprednisolone in traumatic spinal cord lesions: For the moment no benefit to the patient
Original languageDutch
Pages (from-to)1061-1064
Number of pages4
JournalNederlands Tijdschrift voor Geneeskunde
Volume142
Issue number19
Publication statusPublished - 9 May 1998

Cite this

@article{582dcbf5775945b8884c84d0c9e0f8ff,
title = "Methylprednisolon bij traumatische dwarslaesie: Voorlopig nog geen baten voor de patient",
abstract = "Ever since the publication in 1990 in The New England Journal of Medicine of a multicentre, randomised, double-blind, placebo-controlled trial on the efficacy of methylprednisolone (MP) in the treatment of acute, traumatic spinal cord injury, the advice is to administer MP as soon as possible to every patient presenting a traumatic spinal cord injury. This recommendation has been followed throughout the world, especially by traumatologists, and seems to be above criticism. However, the results of most cited studies, which have had a major influence on the treatment of patients with an acute, traumatic spinal cord lesion, show that the improvements in the neurological condition due to MP cannot be translated into a specific improvement in the functional status. Until it has been proven beyond reasonable doubt that MP can play a significant role in the treatment of these patients, we advise that MP should not be administered to a patient with acute, traumatic spinal cord injury, awaiting the results of more quantitative research. Such research is being performed by the Cochrane Brain and Spinal Cord Injury Group.",
author = "Vandertop, {W. P.} and Notermans, {N. C.} and A. Algra",
year = "1998",
month = "5",
day = "9",
language = "Dutch",
volume = "142",
pages = "1061--1064",
journal = "Nederlands Tijdschrift voor Geneeskunde",
issn = "0028-2162",
publisher = "Bohn Stafleu van Loghum",
number = "19",

}

Methylprednisolon bij traumatische dwarslaesie : Voorlopig nog geen baten voor de patient. / Vandertop, W. P.; Notermans, N. C.; Algra, A.

In: Nederlands Tijdschrift voor Geneeskunde, Vol. 142, No. 19, 09.05.1998, p. 1061-1064.

Research output: Contribution to journalReview articleAcademicpeer-review

TY - JOUR

T1 - Methylprednisolon bij traumatische dwarslaesie

T2 - Voorlopig nog geen baten voor de patient

AU - Vandertop, W. P.

AU - Notermans, N. C.

AU - Algra, A.

PY - 1998/5/9

Y1 - 1998/5/9

N2 - Ever since the publication in 1990 in The New England Journal of Medicine of a multicentre, randomised, double-blind, placebo-controlled trial on the efficacy of methylprednisolone (MP) in the treatment of acute, traumatic spinal cord injury, the advice is to administer MP as soon as possible to every patient presenting a traumatic spinal cord injury. This recommendation has been followed throughout the world, especially by traumatologists, and seems to be above criticism. However, the results of most cited studies, which have had a major influence on the treatment of patients with an acute, traumatic spinal cord lesion, show that the improvements in the neurological condition due to MP cannot be translated into a specific improvement in the functional status. Until it has been proven beyond reasonable doubt that MP can play a significant role in the treatment of these patients, we advise that MP should not be administered to a patient with acute, traumatic spinal cord injury, awaiting the results of more quantitative research. Such research is being performed by the Cochrane Brain and Spinal Cord Injury Group.

AB - Ever since the publication in 1990 in The New England Journal of Medicine of a multicentre, randomised, double-blind, placebo-controlled trial on the efficacy of methylprednisolone (MP) in the treatment of acute, traumatic spinal cord injury, the advice is to administer MP as soon as possible to every patient presenting a traumatic spinal cord injury. This recommendation has been followed throughout the world, especially by traumatologists, and seems to be above criticism. However, the results of most cited studies, which have had a major influence on the treatment of patients with an acute, traumatic spinal cord lesion, show that the improvements in the neurological condition due to MP cannot be translated into a specific improvement in the functional status. Until it has been proven beyond reasonable doubt that MP can play a significant role in the treatment of these patients, we advise that MP should not be administered to a patient with acute, traumatic spinal cord injury, awaiting the results of more quantitative research. Such research is being performed by the Cochrane Brain and Spinal Cord Injury Group.

UR - http://www.scopus.com/inward/record.url?scp=0032499511&partnerID=8YFLogxK

M3 - Review article

VL - 142

SP - 1061

EP - 1064

JO - Nederlands Tijdschrift voor Geneeskunde

JF - Nederlands Tijdschrift voor Geneeskunde

SN - 0028-2162

IS - 19

ER -